This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (28)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Donald McCaughan, MD

Arch Intern Med. 1981;141(11):1428-1432.

Abstract
• Probucol, a serum cholesterol-lowering agent, was studied in a double-blind, placebo-controlled trial for one year in 118 hypercholesterolemic men. The mean decrease in the level of serum cholesterol in the probucol group (N = 88) from baseline for months 6 through 12 ranged from 16.2% to 20.9%. The mean decrease from baseline for the placebo-treated patients (N = 30) ranged from 5.2% to 12.7%. The difference between the groups was highly significant. At the end of this one-year trial, 61 of the probucol-treated patients continued receiving therapy in an open trial for up to seven years. After the second year of probucol treatment, the reduction in serum cholesterol levels ranged from 23.1% to 27.4% and was subsequently maintained. The present report shows that probucol is safe and effective for the long-term lowering of serum cholesterol levels in patients with primary hypercholesterolemia.

(Arch Intern Med 1981;141:1428-1432)

Author Affiliations
From the Department of Medicine, Veterans Administration Medical Center, West Roxbury, Mass; The Peter Bent Brigham Hospital, Boston; and Harvard Medical School, Cambridge, Mass.

Footnotes
Accepted for publication Feb 2, 1981.

Read in part before the annual meeting of the American Oil Chemists Society, New Orleans, April 24, 1976.

Reprint requests to the VA Outpatient Clinic, 595 Main St, Worcester, MA 01601 (Dr McCaughan).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials
Pignone et al.
BMJ 2000;321:983-986.
ABSTRACT | FULL TEXT  

Systematic Review on the Risk and Benefit of Different Cholesterol-Lowering Interventions
Bucher et al.
Arterioscler. Thromb. Vasc. Bio. 1999;19:187-195.
ABSTRACT | FULL TEXT  

Meta-analysis, Clinical Trials, and Transferability of Research Results Into Practice: The Case of Cholesterol-Lowering Interventions in the Secondary Prevention of Coronary Heart Disease
Marchioli et al.
Arch Intern Med 1996;156:1158-1172.
ABSTRACT  

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
Law et al.
BMJ 1994;308:367-372.
ABSTRACT | FULL TEXT  

Reducing High Blood Cholesterol Level With Drugs: Cost-effectiveness of Pharmacologic Management
Schulman et al.
JAMA 1990;264:3025-3033.
ABSTRACT